Stock Report: Momenta Pharmaceuticals Inc. (MNTA) Report Updated: May 20, 2013 | Print This Page

Momenta Pharmaceuticals, Inc., a biotechnology company, specializes in the structural characterization, process engineering, and biologic systems analysis of complex molecules. These complex molecules include polysaccharides, polypeptides, and proteins and antibodies. Its technologies are used to develop a product portfolio of complex generic, follow-on biologic, and novel therapeutics. It offers Enoxaparin sodium injection, a generic version of Lovenox to prevent and treat deep vein thrombosis, and to support the treatment of acute coronary syndromes (ACS). The company’s products also include M356, a generic version of Copaxone under FDA review for the reduction of the frequency of relapses in patients with relapsing-remitting multiple sclerosis; M402, a novel polysaccharide-based drug candidate that is in development as a potential anti-cancer agent; Adomiparin, a polysaccharide-based drug candidate, which supports the treatment of ACS; and interchangeable biologics and biosimilar versions of marketed therapeutic proteins. Momenta Pharmaceuticals, Inc. has collaboration agreements with Sandoz AG; Baxter International, Inc.; Baxter Healthcare Corporation; and Baxter Healthcare SA. The company was formerly known as Mimeon, Inc. and changed its name to Momenta Pharmaceuticals, Inc. in September 2002. Momenta Pharmaceuticals, Inc. was founded in 2001 and is based in Cambridge, Massachusetts.